Kymera Therapeutics (KYMR) Current Deferred Revenue (2019 - 2025)

Kymera Therapeutics (KYMR) has 7 years of Current Deferred Revenue data on file, last reported at $34.4 million in Q4 2025.

• Current Deferred Revenue for Q4 2025 came in at $34.4 million, up 153.13% year-over-year; the trailing twelve-month figure through Dec 2025 was $34.4 million (up 153.13% YoY), and the FY2025 annual result was $34.4 million, up 153.13% from the prior year.
• Current Deferred Revenue grew to $34.4 million in Q4 2025 per KYMR's latest filing, from $23.3 million in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $101.0 million in Q4 2021 and troughed at $11.5 million in Q1 2025.
• A 5-year average of $45.4 million and a median of $36.6 million in 2022 frame the typical range for Current Deferred Revenue.
• The sharpest annual moves came in 2023 and 2025: Current Deferred Revenue tumbled 70.91% in 2023, then surged 153.13% in 2025.
• A 5-year view of Current Deferred Revenue shows it stood at $101.0 million in 2021, then plunged by 65.1% to $35.3 million in 2022, then rose by 7.44% to $37.9 million in 2023, then slumped by 64.16% to $13.6 million in 2024, then surged by 153.13% to $34.4 million in 2025.
• Business Quant data shows KYMR's Current Deferred Revenue at $34.4 million in Q4 2025, $23.3 million in Q3 2025, and $40.0 million in Q2 2025.